IMPAACT 2008

Study Title: Phase I/II Multisite, Randomized, Controlled Study of Monoclonal Antibody VRC01 with Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants

 Protocol summary:

IMPAACT 2008 is a Phase I/II, multisite, randomized controlled study of monoclonal antibody VRC01 combined with antiretroviral therapy in infants. The study is designed to assess the safety of VRC01 administered with ART (through Week 14) and the effect of VRC01 on HIV-1 DNA concentrations in peripheral blood (at Week 14) among HIV-1-infected infants. The study is closed to follow-up.

 Location: HFC CRS

IMPAACT

Current Study

Comments are closed.